The DOI matches its Crossref record; 112 of the 112 references it cites were found in a registry or an index.
Rapamycin reverses hypertrophic cardiomyopathy in a mouse model of LEOPARD syndrome–associated PTPN11 mutation
Open accessAbstract
LEOPARD syndrome (LS) is an autosomal dominant "RASopathy" that manifests with congenital heart disease. Nearly all cases of LS are caused by catalytically inactivating mutations in the protein tyrosine phosphatase (PTP), non-receptor type 11 (PTPN11) gene that encodes the SH2 domain-containing PTP-2 (SHP2). RASopathies typically affect components of the RAS/MAPK pathway, yet it remains unclear how PTPN11 mutations alter cellular signaling to produce LS phenotypes. We therefore generated knockin mice harboring the Ptpn11 mutation Y279C, one of the most common LS alleles. Ptpn11(Y279C/+) (LS/+) mice recapitulated the human disorder, with short stature, craniofacial dysmorphia, and morphologic, histologic, echocardiographic, and molecular evidence of hypertrophic cardiomyopathy (HCM). Heart and/or cardiomyocyte lysates from LS/+ mice showed enhanced binding of Shp2 to Irs1, decreased Shp2 catalytic activity, and abrogated agonist-evoked Erk/Mapk signaling. LS/+ mice also exhibited increased basal and agonist-induced Akt and mTor activity. The cardiac defects in LS/+ mice were completely reversed by treatment with rapamycin, an inhibitor of mTOR. Our results demonstrate that LS mutations have dominant-negative effects in vivo, identify enhanced mTOR activity as critical for causing LS-associated HCM, and suggest that TOR inhibitors be considered for treatment of HCM in LS patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts
Thum, T., Gross, C., Fiedler, J., Fischer, T., Kissler, S., Bussen, M., Galuppo, P., Just, S., Rottbauer, W., Frantz, S., et al. (2008) · Nature · doi:10.1038/nature07511 · Cited by 2,349
Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome
Tartaglia, M., Mehler, E. L., Goldberg, R., Zampino, G., Brunner, H. G., Kremer, H., van der Burgt, I., Crosby, A. H., Ion, A., Jeffery, S., et al. (2001) · Nature Genetics · doi:10.1038/ng772 · Cited by 1,733
The ‘Shp'ing news: SH2 domain-containing tyrosine phosphatases in cell signaling
Neel, B. G., Gu, H., & Pao, L. (2003) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(03)00091-4 · Cited by 1,249
Self-citationA Highly Efficient Recombineering-Based Method for Generating Conditional Knockout Mutations
Liu, P., Jenkins, N. A., & Copeland, N. G. (2003) · Genome Research · doi:10.1101/gr.749203 · Cited by 1,013
Crystal Structure of the Tyrosine Phosphatase SHP-2
Hof, P., Pluskey, S., Dhe-Paganon, S., Eck, M. J., & Shoelson, S. E. (1998) · Cell · doi:10.1016/s0092-8674(00)80938-1 · Cited by 985
Fujio, Y., Nguyen, T., Wencker, D., Kitsis, R. N., & Walsh, K. (2000) · Circulation · doi:10.1161/01.cir.101.6.660 · Cited by 847
Tartaglia, M., Kalidas, K., Shaw, A., Song, X., Musat, D. L., van der Burgt, I., Brunner, H. G., Bertola, D. R., Crosby, A., Ion, A., et al. (2002) · The American Journal of Human Genetics · doi:10.1086/340847 · Cited by 802
Roles of Growth Hormone and Insulin-like Growth Factor 1 in Mouse Postnatal Growth
Lupu, F., Terwilliger, J. D., Lee, K., Segre, G. V., & Efstratiadis, A. (2001) · Developmental Biology · doi:10.1006/dbio.2000.9975 · Cited by 771
Niimura, H., Bachinski, L. L., Sangwatanaroj, S., Watkins, H., Chudley, A. E., McKenna, W., Kristinsson, A., Roberts, R., Sole, M., Maron, B. J., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199804303381802 · Cited by 761
Germline KRAS mutations cause Noonan syndrome
Schubbert, S., Zenker, M., Rowe, S. L., Böll, S., Klein, C., Bollag, G., van der Burgt, I., Musante, L., Kalscheuer, V., Wehner, L.-E., et al. (2006) · Nature Genetics · doi:10.1038/ng1748 · Cited by 730
Gain-of-function RAF1 mutations cause Noonan and LEOPARD syndromes with hypertrophic cardiomyopathy
Pandit, B., Sarkozy, A., Pennacchio, L. A., Carta, C., Oishi, K., Martinelli, S., Pogna, E. A., Schackwitz, W., Ustaszewska, A., Landstrom, A., et al. (2007) · Nature Genetics · doi:10.1038/ng2073 · Cited by 698
Patient-specific induced pluripotent stem-cell-derived models of LEOPARD syndrome
Carvajal-Vergara, X., Sevilla, A., D’Souza, S. L., Ang, Y.-S., Schaniel, C., Lee, D.-F., Yang, L., Kaplan, A. D., Adler, E. D., Rozov, R., et al. (2010) · Nature · doi:10.1038/nature09005 · Cited by 690
SH2-Containing Phosphotyrosine Phosphatase as a Target of Protein-Tyrosine Kinases
Feng, G.-S., Hui, C.-C., & Pawson, T. (1993) · Science · doi:10.1126/science.8096088 · Cited by 661
Molecular Regulation of Atrioventricular Valvuloseptal Morphogenesis
Eisenberg, L. M., & Markwald, R. R. (1995) · Circulation Research · doi:10.1161/01.res.77.1.1 · Cited by 648
Protein kinase cascades in the regulation of cardiac hypertrophy
Dorn, G. W., & Force, T. L. (2005) · Journal of Clinical Investigation · doi:10.1172/jci200524178 · Cited by 638
Nakagawa, O., Ogawa, Y., Itoh, H., Suga, S., Komatsu, Y., Kishimoto, I., Nishino, K., Yoshimasa, T., & Nakao, K. (1995) · Journal of Clinical Investigation · doi:10.1172/jci118162 · Cited by 617
Agah, R., Frenkel, P. A., French, B. A., Michael, L. H., Overbeek, P. A., & Schneider, M. D. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119509 · Cited by 606
Germline gain-of-function mutations in SOS1 cause Noonan syndrome
Roberts, A. E., Araki, T., Swanson, K. D., Montgomery, K. T., Schiripo, T. A., Joshi, V. A., Li, L., Yassin, Y., Tamburino, A. M., Neel, B. G., et al. (2007) · Nature Genetics · doi:10.1038/ng1926 · Cited by 605
Self-citationThe conserved phosphoinositide 3-kinase pathway determines heart size in mice
Shioi, T. (2000) · The EMBO Journal · doi:10.1093/emboj/19.11.2537 · Cited by 604
Gain-of-function SOS1 mutations cause a distinctive form of Noonan syndrome
Tartaglia, M., Pennacchio, L. A., Zhao, C., Yadav, K. K., Fodale, V., Sarkozy, A., Pandit, B., Oishi, K., Martinelli, S., Schackwitz, W., et al. (2007) · Nature Genetics · doi:10.1038/ng1939 · Cited by 586
Cardiac Fibroblasts Regulate Myocardial Proliferation through β1 Integrin Signaling
Ieda, M., Tsuchihashi, T., Ivey, K. N., Ross, R. S., Hong, T.-T., Shaw, R. M., & Srivastava, D. (2009) · Developmental Cell · doi:10.1016/j.devcel.2008.12.007 · Cited by 580
Regulation of Myocardial Contractility and Cell Size by Distinct PI3K-PTEN Signaling Pathways
Crackower, M. A., Oudit, G. Y., Kozieradzki, I., Sarao, R., Sun, H., Sasaki, T., Hirsch, E., Suzuki, A., Shioi, T., Irie-Sasaki, J., et al. (2002) · Cell · doi:10.1016/s0092-8674(02)00969-8 · Cited by 576
McMullen, J. R., Shioi, T., Zhang, L., Tarnavski, O., Sherwood, M. C., Kang, P. M., & Izumo, S. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1934654100 · Cited by 534
Akt/Protein Kinase B Promotes Organ Growth in Transgenic Mice
Shioi, T., McMullen, J. R., Kang, P. M., Douglas, P. S., Obata, T., Franke, T. F., Cantley, L. C., & Izumo, S. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.8.2799-2809.2002 · Cited by 506
Combinatorial control of the specificity of protein tyrosine phosphatases
Tonks, N. K., & Neel, B. G. (2001) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(00)00196-4 · Cited by 501
Self-citationGermline gain-of-function mutations in RAF1 cause Noonan syndrome
Razzaque, M. A., Nishizawa, T., Komoike, Y., Yagi, H., Furutani, M., Amo, R., Kamisago, M., Momma, K., Katayama, H., Nakagawa, M., et al. (2007) · Nature Genetics · doi:10.1038/ng2078 · Cited by 498
Patrucco, E., Notte, A., Barberis, L., Selvetella, G., Maffei, A., Brancaccio, M., Marengo, S., Russo, G., Azzolino, O., Rybalkin, S. D., et al. (2004) · Cell · doi:10.1016/j.cell.2004.07.017 · Cited by 468
Rapamycin Attenuates Load-Induced Cardiac Hypertrophy in Mice
Shioi, T., McMullen, J. R., Tarnavski, O., Converso, K., Sherwood, M. C., Manning, W. J., & Izumo, S. (2003) · Circulation · doi:10.1161/01.cir.0000057979.36322.88 · Cited by 462
Mutations in PTPN11 implicate the SHP-2 phosphatase in leukemogenesis
Loh, M. L. (2004) · Blood · doi:10.1182/blood-2003-09-3287 · Cited by 427
Grouping of Multiple-Lentigines/LEOPARD and Noonan Syndromes on the PTPN11 Gene
Digilio, M. C., Conti, E., Sarkozy, A., Mingarelli, R., Dottorini, T., Marino, B., Pizzuti, A., & Dallapiccola, B. (2002) · The American Journal of Human Genetics · doi:10.1086/341528 · Cited by 421
Araki, T., Mohi, M. G., Ismat, F. A., Bronson, R. T., Williams, I. R., Kutok, J. L., Yang, W., Pao, L. I., Gilliland, D. G., Epstein, J. A., et al. (2004) · Nature Medicine · doi:10.1038/nm1084 · Cited by 420
Self-citationCordeddu, V., Di Schiavi, E., Pennacchio, L. A., Ma'ayan, A., Sarkozy, A., Fodale, V., Cecchetti, S., Cardinale, A., Martin, J., Schackwitz, W., et al. (2009) · Nature Genetics · doi:10.1038/ng.425 · Cited by 419
Diversity and functional consequences of germline and somatic PTPN11 mutations in human disease
Tartaglia, M., Martinelli, S., Stella, L., Bocchinfuso, G., Flex, E., Cordeddu, V., Zampino, G., van der Burgt, I., Palleschi, A., Petrucci, T. C., et al. (2006) · The American Journal of Human Genetics · doi:10.1086/499925 · Cited by 415
Electrotonic Modulation of Cardiac Impulse Conduction by Myofibroblasts
Miragoli, M., Gaudesius, G., & Rohr, S. (2006) · Circulation Research · doi:10.1161/01.res.0000214537.44195.a3 · Cited by 390
Cardiac fibroblasts are essential for the adaptive response of the murine heart to pressure overload
Takeda, N., Manabe, I., Uchino, Y., Eguchi, K., Matsumoto, S., Nishimura, S., Shindo, T., Sano, M., Otsu, K., Snider, P., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci40295 · Cited by 389
Three-Dimensional Structures of Acidic and Basic Fibroblast Growth Factors
Zhu, X., Komiya, H., Chirino, A., Faham, S., Fox, G. M., Arakawa, T., Hsu, B. T., & Rees, D. C. (1991) · Science · doi:10.1126/science.1702556 · Cited by 386
The tyrosine phosphatase Shp2 (PTPN11) in cancer
Chan, G., Kalaitzidis, D., & Neel, B. G. (2008) · Cancer and Metastasis Reviews · doi:10.1007/s10555-008-9126-y · Cited by 382
Self-citationNOONAN SYNDROME AND RELATED DISORDERS: Genetics and Pathogenesis
Tartaglia, M., & Gelb, B. D. (2005) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev.genom.6.080604.162305 · Cited by 355
Wang, Y., Su, B., Sah, V. P., Brown, J. H., Han, J., & Chien, K. R. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.10.5423 · Cited by 339
PTPN11 (Shp2) Mutations in LEOPARD Syndrome Have Dominant Negative, Not Activating, Effects
Kontaridis, M. I., Swanson, K. D., David, F. S., Barford, D., & Neel, B. G. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m513068200 · Cited by 338
Self-citationLiao, R., Jain, M., Cui, L., D’Agostino, J., Aiello, F., Luptak, I., Ngoy, S., Mortensen, R. M., & Tian, R. (2002) · Circulation · doi:10.1161/01.cir.0000034049.61181.f3 · Cited by 333
Revealing mechanisms for SH2 domain mediated regulation of the protein tyrosine phosphatase SHP-2
Barford, D., & Neel, B. G. (1998) · Structure · doi:10.1016/s0969-2126(98)00027-6 · Cited by 321
Self-citationA restricted spectrum of NRAS mutations causes Noonan syndrome
Cirstea, I. C., Kutsche, K., Dvorsky, R., Gremer, L., Carta, C., Horn, D., Roberts, A. E., Lepri, F., Merbitz-Zahradnik, T., König, R., et al. (2010) · Nature Genetics · doi:10.1038/ng.497 · Cited by 315
Diverse Biochemical Properties of Shp2 Mutants
Keilhack, H., David, F. S., McGregor, M., Cantley, L. C., & Neel, B. G. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m504699200 · Cited by 298
Self-citationSarkozy, A., Digilio, M. C., & Dallapiccola, B. (2008) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-3-13 · Cited by 293
Anan, R., Greve, G., Thierfelder, L., Watkins, H., McKenna, W. J., Solomon, S., Vecchio, C., Shono, H., Nakao, S., & Tanaka, H. (1994) · Journal of Clinical Investigation · doi:10.1172/jci116957 · Cited by 286
Shp-2 Tyrosine Phosphatase: Signaling One Cell or Many
Feng, G.-S. (1999) · Experimental Cell Research · doi:10.1006/excr.1999.4668 · Cited by 285
Zhang, S. Q., Tsiaras, W. G., Araki, T., Wen, G., Minichiello, L., Klein, R., & Neel, B. G. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.12.4062-4072.2002 · Cited by 282
Self-citationThe Role of the Mammalian Target Of Rapamycin (mTOR) in Renal Disease
Lieberthal, W., & Levine, J. S. (2009) · Journal of the American Society of Nephrology · doi:10.1681/asn.2008111186 · Cited by 280
PTPN11 mutations in LEOPARD syndrome
Legius, E., Schrander-Stumpel, C., Schollen, E., Pulles-Heintzberger, C., Gewillig, M., & Fryns, J.-P. (2002) · Journal of Medical Genetics · doi:10.1136/jmg.39.8.571 · Cited by 274
Rapamycin Ameliorates PKD Resulting from Conditional Inactivation of Pkd1
Shillingford, J. M., Piontek, K. B., Germino, G. G., & Weimbs, T. (2010) · Journal of the American Society of Nephrology · doi:10.1681/asn.2009040421 · Cited by 263
Marino, B., Digilio, M. C., Toscano, A., Giannotti, A., & Dallapiccola, B. (1999) · The Journal of Pediatrics · doi:10.1016/s0022-3476(99)70088-0 · Cited by 258
Cardiac remodelling: concentric versus eccentric hypertrophy in strength and endurance athletes
Mihl, C., Dassen, W. R. M., & Kuipers, H. (2008) · Netherlands Heart Journal · doi:10.1007/bf03086131 · Cited by 249
Noonan Syndrome: Clinical Aspects and Molecular Pathogenesis
Tartaglia, M., Zampino, G., & Gelb, B. D. (2010) · Molecular Syndromology · doi:10.1159/000276766 · Cited by 246
Wu, X., Simpson, J., Hong, J. H., Kim, K.-H., Thavarajah, N. K., Backx, P. H., Neel, B. G., & Araki, T. (2011) · Journal of Clinical Investigation · doi:10.1172/jci44929 · Cited by 234
Self-citationSadoshima, J., & Izumo, S. (1995) · Circulation Research · doi:10.1161/01.res.77.6.1040 · Cited by 229
Recent Advances in the Molecular Genetics of Hypertrophic Cardiomyopathy
Marian, A. J., & Roberts, R. (1995) · Circulation · doi:10.1161/01.cir.92.5.1336 · Cited by 209
Mattoon, D. R., Lamothe, B., Lax, I., & Schlessinger, J. (2004) · BMC Biology · doi:10.1186/1741-7007-2-24 · Cited by 207
Sarkozy, A., Conti, E., Seripa, D., Digilio, M. C., Grifone, N., Tandoi, C., Fazio, V. M., Di Ciommo, V, Marino, B., Pizzuti, A., et al. (2003) · Journal of Medical Genetics · doi:10.1136/jmg.40.9.704 · Cited by 203
Burch, M., Sharland, M., Shinebourne, E., Smith, G., Patton, M., & McKenna, W. (1993) · Journal of the American College of Cardiology · doi:10.1016/0735-1097(93)90436-5 · Cited by 201
Fragale, A., Tartaglia, M., Wu, J., & Gelb, B. D. (2004) · Human Mutation · doi:10.1002/humu.20005 · Cited by 194
The mTOR pathway and its role in human genetic diseases
ROSNER, M., HANNEDER, M., SIEGEL, N., VALLI, A., FUCHS, C., & HENGSTSCHLAGER, M. (2008) · Mutation Research/Reviews in Mutation Research · doi:10.1016/j.mrrev.2008.06.001 · Cited by 182
Molecular Basis of Familial Cardiomyopathies
Schwartz, K., Carrier, L., Guicheney, P., & Komajda, M. (1995) · Circulation · doi:10.1161/01.cir.91.2.532 · Cited by 179
Wu, C.-J., O'Rourke, D. M., Feng, G.-S., Johnson, G. R., Wang, Q., & Greene, M. I. (2001) · Oncogene · doi:10.1038/sj.onc.1204699 · Cited by 178
Boluyt, M. O., Zheng, J.-S., Younes, A., Long, X., O’Neill, L., Silverman, H., Lakatta, E. G., & Crow, M. T. (1997) · Circulation Research · doi:10.1161/01.res.81.2.176 · Cited by 169
Inhibition of mTOR reduces chronic pressure-overload cardiac hypertrophy and fibrosis
Gao, X.-M., Wong, G., Wang, B., Kiriazis, H., Moore, X.-L., Su, Y.-D., Dart, A., & Du, X.-J. (2006) · Journal of Hypertension · doi:10.1097/01.hjh.0000239304.01496.83 · Cited by 160
Self-citationSignaling pathways mediating cardiac myocyte gene expression in physiological and stress responses
Clerk, A., Cullingford, T. E., Fuller, S. J., Giraldo, A., Markou, T., Pikkarainen, S., & Sugden, P. H. (2007) · Journal of Cellular Physiology · doi:10.1002/jcp.21094 · Cited by 160
Functional analysis of leukemia-associated PTPN11 mutations in primary hematopoietic cells
Schubbert, S., Lieuw, K. H., Rowe, S. L., Lee, C. M., Li, X., Loh, M. L., Clapp, D. W., & Shannon, K. (2005) · Blood · doi:10.1182/blood-2004-11-4207 · Cited by 159
LEOPARD syndrome: Clinical diagnosis in the first year of life
Digilio, M. C., Sarkozy, A., de Zorzi, A., Pacileo, G., Limongelli, G., Mingarelli, R., Calabrò, R., Marino, B., & Dallapiccola, B. (2006) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.31156 · Cited by 158
Functional analysis of PTPN11/SHP-2 mutants identified in Noonan syndrome and childhood leukemia
Niihori, T., Aoki, Y., Ohashi, H., Kurosawa, K., Kondoh, T., Ishikiriyama, S., Kawame, H., Kamasaki, H., Yamanaka, T., Takada, F., et al. (2005) · Journal of Human Genetics · doi:10.1007/s10038-005-0239-7 · Cited by 147
Wang, L., & Proud, C. G. (2002) · Circulation Research · doi:10.1161/01.res.0000041029.97988.e9 · Cited by 141
Raptor and mTOR: Subunits of a Nutrient-Sensitive Complex
Kim, D., & Sabatini, D. M. (2004) · Current topics in microbiology and immunology · doi:10.1007/978-3-642-18930-2_15 · Cited by 134
Chen, P., Wakimoto, H., Conner, D. A., Araki, T., Yuan, T., Roberts, A. E., Seidman, C. E., Bronson, R. T., Neel, B. G., Seidman, J. G., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci43910 · Cited by 134
Self-citationAraki, T., Chan, G., Newbigging, S., Morikawa, L., Bronson, R. T., & Neel, B. G. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0810053106 · Cited by 131
Self-citationNoonan, Costello and cardio–facio–cutaneous syndromes: dysregulation of the Ras–MAPK pathway
Tidyman, W. E., & Rauen, K. A. (2008) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399408000902 · Cited by 127
Rapamycin regulates Akt and ERK phosphorylation through mTORC1 and mTORC2 signaling pathways
Chen, X., Liu, F., Song, X., Wang, Z., Dong, Z., Hu, Z., Lan, R., Guan, W., Zhou, T., Xu, X., et al. (2010) · Molecular Carcinogenesis · doi:10.1002/mc.20628 · Cited by 125
Wang, L., Wang, X., & Proud, C. G. (2000) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.2000.278.4.h1056 · Cited by 124
Stewart, R. A., Sanda, T., Widlund, H. R., Zhu, S., Swanson, K. D., Hurley, A., Bentires‐Alj, M., Fisher, D. E., Kontaridis, M. I., Look, A. T., et al. (2010) · Developmental Cell · doi:10.1016/j.devcel.2010.03.009 · Cited by 121
Self-citationHRAS and the Costello syndrome
Rauen, K. (2007) · Clinical Genetics · doi:10.1111/j.1399-0004.2007.00743.x · Cited by 119
Reduced phosphatase activity of SHP‐2 in LEOPARD syndrome: Consequences for PI3K binding on Gab1
Hanna, N., Montagner, A., Lee, W. H., Miteva, M. A., Vidal, M., Vidaud, M., Parfait, B., & Raynal, P. (2006) · FEBS Letters · doi:10.1016/j.febslet.2006.03.088 · Cited by 117
Structural Determinants of SHP-2 Function and Specificity in Xenopus Mesoderm Induction
O’Reilly, A. M., & Neel, B. G. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.1.161 · Cited by 116
Self-citationÉdouard, T., Combier, J., Nédélec, A., Bel-Vialar, S., Metrich, M., Conte-Auriol, F., Lyonnet, S., Parfait, B., Tauber, M., Salles, J., et al. (2010) · Molecular and Cellular Biology · doi:10.1128/mcb.00646-09 · Cited by 108
Oishi, K., Zhang, H., Gault, W. J., Wang, C. J., Tan, C. C., Kim, I.-K., Ying, H., Rahman, T., Pica, N., Tartaglia, M., et al. (2008) · Human Molecular Genetics · doi:10.1093/hmg/ddn336 · Cited by 103
Shp2 Knockdown and Noonan/LEOPARD Mutant Shp2–Induced Gastrulation Defects
Jopling, C., van Geemen, D., & den Hertog, J. (2007) · PLoS Genetics · doi:10.1371/journal.pgen.0030225 · Cited by 101
Role of ERK1/2 signaling in congenital valve malformations in Noonan syndrome
Krenz, M., Gulick, J. M., Osińska, H. E., Colbert, M. C., Molkentin, J. D., & Robbins, J. M. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0806556105 · Cited by 96
Kontaridis, M. I., Yang, W., Bence, K. K., Cullen, D., Wang, B., Bodyak, N. D., Ke, Q., Hinek, A., Kang, P. M., Liao, R., et al. (2008) · Circulation · doi:10.1161/circulationaha.107.728865 · Cited by 94
Self-citationSoesanto, W. S., Lin, H.-Y., Hu, E. M., Lefler, S., Litwin, S. E., Sena, S., Abel, E. D., Symons, J. D., & Jalili, T. (2009) · Hypertension · doi:10.1161/hypertensionaha.109.138818 · Cited by 89
Hakak, Y., Hsu, Y. S., & Martin, G. S. (2000) · Oncogene · doi:10.1038/sj.onc.1203655 · Cited by 78
The face of Noonan syndrome: Does phenotype predict genotype
Allanson, J. E., Bohring, A., Dörr, H., Dufke, A., Gillessen‐Kaesbach, G., Horn, D., König, R., Kratz, C. P., Kutsche, K., Pauli, S., et al. (2010) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.33518 · Cited by 74
Lee, N. Y., Woodrum, C., Nobil, A. M., Rauktys, A., Messina, M. P., & Dabora, S. L. (2009) · BMC Pharmacology · doi:10.1186/1471-2210-9-8 · Cited by 74
Marin, T. M., Clemente, C. F. M. Z., dos Santos, A. M., Picardi, P. K., Pascoal, V., Lopes‐Cendes, Í., Saad, M. J. A., & Franchini, K. G. (2008) · Circulation Research · doi:10.1161/circresaha.108.179754 · Cited by 69
Self-citationShen, W., Chen, Z., Shi, S., Chen, H., Zhu, W., Penner, A. E., Bu, G., Li, W., Boyle, D. W., Rubart, M., et al. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m801510200 · Cited by 68
Hypertrophic cardiomyopathy in childhood
Maron, B. J. (2004) · Pediatric Clinics of North America · doi:10.1016/j.pcl.2004.04.017 · Cited by 66
The genetics of congenital heart disease: a review of recent developments
Weismann, C. G., & Gelb, B. D. (2007) · Current Opinion in Cardiology · doi:10.1097/hco.0b013e3280f629c7 · Cited by 64
Schiekofer, S., Shiojima, I., Sato, K., Galasso, G., Oshima, Y., & Walsh, K. X. (2006) · Physiological Genomics · doi:10.1152/physiolgenomics.00234.2005 · Cited by 59
The Leopard (multiple lentigines) syndrome revisited.
Rj, G., Rc, A., & Jh, M. (1971) · PubMed · Cited by 59
Ng, D. (2003) · Cardiovascular Research · doi:10.1016/s0008-6363(02)00664-8 · Cited by 58
Distinct Molecular Phenotypes in Murine Cardiac Muscle Development, Growth, and Hypertrophy
Schoenfeld, J., Vasser, M., Jhurani, P., Ng, P., Hunter, J. J., Ross, J., Chien, K. R., & Lowe, D. G. (1998) · Journal of Molecular and Cellular Cardiology · doi:10.1006/jmcc.1998.0787 · Cited by 58
Altered Glucose Homeostasis in Mice with Liver-specific Deletion of Src Homology Phosphatase 2
Matsuo, K., Delibegović, M., Matsuo, I., Nagata, N., Liu, S., Bettaieb, A., Xi, Y., Araki, K., Yang, W., Kahn, B. B., et al. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.153734 · Cited by 57
Self-citationSerra, A. L., Kistler, A. D., Poster, D., Struker, M., Wuthrich, R. P., Weishaupt, D., & Tschirch, F. T. C. (2007) · BMC Nephrology · doi:10.1186/1471-2369-8-13 · Cited by 57
Chen, J., Lü, Y., Zhang, H., Ding, Y., Ren, C., Hua, Z., Zhou, Y., Deng, B., Jin, G., Hu, Z., et al. (2010) · Molecular Carcinogenesis · doi:10.1002/mc.20661 · Cited by 55
Hypertrophic cardiomyopathy: current understanding and treatment objectives
Soor, G. S., Luk, A. O. Y., Ahn, E., Abraham, J. R., Woo, A., Ralph-Edwards, A. C., & BUTANY, J. W. (2008) · Journal of Clinical Pathology · doi:10.1136/jcp.2008.061655 · Cited by 51
Evaluating Temsirolimus Activity in Multiple Tumors: A Review of Clinical Trials
Dancey, J. E., Curiel, R. E., & Purvis, J. D. (2009) · Seminars in Oncology · doi:10.1053/j.seminoncol.2009.10.010 · Cited by 50
Hypertrophic cardiomyopathy in Noonan syndrome
Nishikawa, T., Ishiyama, S., Shimojo, T., Takeda, K., KASAJIMA, T., & Momma, K. (1996) · Pediatrics International · doi:10.1111/j.1442-200x.1996.tb03445.x · Cited by 49
Genetic and Pathogenetic Aspects of Noonan Syndrome and Related Disorders
Zenker, M. (2009) · Hormone Research in Paediatrics · doi:10.1159/000243782 · Cited by 48
Two novel and one recurrent PTPN11 mutations in LEOPARD syndrome
Yoshida, R. Y., Nagai, T., Hasegawa, T., Kinoshita, E., Tanaka, T., & Ogata, T. (2004) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.30281 · Cited by 32
PTPN11 mutations and genotype-phenotype correlations in Noonan and LEOPARD syndromes.
Ogata, T., & Yoshida, R. Y. (2005) · PubMed · Cited by 32
Potential Pharmacological Interventions in Polycystic Kidney Disease
Masoumi, A., Gitomer, B. Y., Kelleher, C. L., & Schrier, R. W. (2007) · Drugs · doi:10.2165/00003495-200767170-00004 · Cited by 30
The genetic basis of pediatric cardiovascular disease
Strauss, A. W., & Johnson, M. C. (1996) · Seminars in Perinatology · doi:10.1016/s0146-0005(96)80069-3 · Cited by 20
Alexandre, J., Raymond, É., & Armand, J. (1999) · PubMed · Cited by 14
Mammalian Target of Rapamycin and Autosomal Dominant Polycystic Kidney Disease
Wuthrich, R. P., & Serra, A. L. (2009) · Transplantation Proceedings · doi:10.1016/j.transproceed.2009.06.097 · Cited by 5
Cited by
New Insights Into the Role of mTOR Signaling in the Cardiovascular System
Sciarretta, S., Forte, M., Frati, G., & Sadoshima, J. (2018) · Circulation Research · doi:10.1161/circresaha.117.311147 · Cited by 491
Mammalian Target of Rapamycin Signaling in Cardiac Physiology and Disease
Sciarretta, S., Volpe, M., & Sadoshima, J. (2014) · Circulation Research · doi:10.1161/circresaha.114.302022 · Cited by 453
Willig, L. K., Petrikin, J. E., Smith, L. D., Saunders, C. J., Thiffault, I., Miller, N. A., Soden, S. E., Cakici, J. A., Herd, S. M., Twist, G., et al. (2015) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(15)00139-3 · Cited by 401
Recent advances in RASopathies
Aoki, Y., Niihori, T., Inoue, S.-I., & Matsubara, Y. (2016) · Journal of Human Genetics · doi:10.1038/jhg.2015.114 · Cited by 373
Ramos, F. J., Chen, S. C., Garelick, M. G., Dai, D.-F., Liao, C.-Y., Schreiber, K. H., MacKay, V. L., An, E. H., Strong, R., Ladiges, W. C., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003802 · Cited by 349
Metadata
- Authors
- Marin, T. M., Keith, K., Davies, B., Conner, D. A., Guha, P., Kalaitzidis, D., Wu, X., Lauriol, J., Wang, B., Bauer, M., Bronson, R., Franchini, K. G., Neel, B. G., & Kontaridis, M. I.
- Venue
- Journal of Clinical Investigation
- Published
- 2011-03-01
- Volume
- 121
- Issue
- 3
- Pages
- 1026-1043
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2118719488
- Cited by
- 282
- References
- 112
- FWCI
- 8.35
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.